HeartCare Medical-B (6609.HK) Records HK$15.5 Billion in Margin Financing, Oversubscribed 136x Amid IPO

Gelonghui, August 12 | Neurointerventional device company HeartCare-B (6609.HK) is currently in its subscription period (August 10 to August 13). Data shows that as of 10:00 today, HeartCare has preliminarily recorded total margin financing of approximately HK$15.528 billion, reflecting an oversubscription ratio of 136 times.

HeartCare is issuing 6.6018 million shares in this offering, with 10% allocated to the public offering, 90% to the international offering, and a 15% over-allotment option. The offer price is HKD 160–171 per share, with each board lot comprising 50 shares. The shares are expected to list on August 20.

It is reported that HeartCare has currently established five major product lines, encompassing mechanical thrombectomy for ischemic stroke, stenosis treatment for ischemic stroke, hemorrhagic stroke treatment, cardioembolic stroke prevention, and vascular access products. Among them, Captor and the Left Atrial Appendage (LAA) occluder are its two core products. Captor has already been commercialized in China, while the LAA occluder is expected to receive NMPA approval in the fourth quarter of this year, with sales scheduled to commence in the second quarter of 2022. (Gelonghui)